Integrated Concateno jumps into the black for H1
This article was originally published in Clinica
Executive Summary
Having completed integration of seven companies it acquired between 2006 and 2007, UK-based drugs-of-abuse testing company Concateno swung into pre-tax profit for the first half of this year. The UK-based firm recorded a pro forma loss of £1.2m a year earlier, but succeeded in pulling itself into the black with pre-tax profit of £0.7m for the first six months of 2008. Revenues during this period went up 14% to £23.3m ($41.8m), helped by particularly strong sales of its products in the workplace (+27%) and medico-legal (+32%) markets. The company said integration of the acquired businesses finished ahead of schedule, enabling it to book £0.8m of integration synergies in the first half. The annualised synergies – which is expected to be around £3m – will be realised in full by the fourth quarter of 2008. In addition to its H1 results, Concateno said that it was still mulling over a potential sale of the company, after being approached by several interested suitors in July (see Clinica No 1314, p 3), and will make a further announcement as appropriate.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.